The need for speed in the management of haemophilia patients with inhibitors.
Rapid control of bleeding is the key to reducing bleeding complications and thereby preserving joint and musculoskeletal function in haemophilia patients with inhibitors. However, this requires early diagnosis following the onset of bleeding and strategies for rapid treatment in an outpatient setting. Overarching themes on the need for speed in managing bleeds in haemophilia patients were examined by a panel of clinicians experienced in managing inhibitor patients and joint disease during the Third Zürich Haemophilia Forum on 8 May 2009. This report summarizes the opinions of the panel on how to achieve rapid bleeding control in inhibitor patients and areas that were identified by the panel for future research or as needing new consensus guidelines. The consensus was that home treatment should be established for haemophilia patients with inhibitors, as it is associated with a faster time to treatment, as well as improvements in the quality of life of patients and their carers. In addition, as improved haemostatic control now allows inhibitor patients to participate in a wider range of physical activities, specific guidelines are required on which types of sport and work are appropriate. It was agreed that clear, systematic approaches are needed for early diagnosis of joint and muscle bleeds in inhibitor patients, which could facilitate rapid treatment. There may be opportunities for exploiting new diagnostic techniques from osteoarthritis to enable earlier diagnosis of haemophilic arthropathy. Overall, it was concluded that greater emphasis should be placed on education and patients' psychological needs, to enable inhibitor patients to cope up more effectively with their disease.
Salek
S Z
SZ
National Haemophilia Centre, University Hospital Centre Zagreb, Rebro, Zagreb, Croatia. silva.zupancic-salek@zg.htnet.hr
Benson
G M
GM
Elezović
I
I
Krenn
V
V
Ljung
R C R
RC
Morfini
M
M
Remor
E
E
Santagostino
E
E
Sørensen
B
B
D042241:Early Diagnosis; D005167:Factor VII / Q000627:therapeutic use*; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D007592:Joint Diseases / Q000175:diagnosis / Q000209:etiology; D009135:Muscular Diseases / Q000188:drug therapy / Q000209:etiology; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII